Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01117038 · ClinicalTrials.gov registry record · Phase 1

Drug Interaction Study of Avanafil and Enalapril or Amlodipine

A Phase 1 study of Erectile Dysfunction, sponsored by VIVUS.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
1
Study location

NCT01117038 is a Phase 1 study of Erectile Dysfunction that has completed, run by VIVUS. The registered enrollment target is 48 participants, below the 230-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01117038, a Phase 1 study of Erectile Dysfunction, has completed, sponsored by VIVUS.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the change in the blood pressure and pulse rate, pharmacokinetics and the safety when avanafil is taken with either enalapril or amlodipine.

Conditions Studied

Interventions

  • DRUG avanafil and enalapril
  • DRUG avanafil and amlodipine

Study Locations (1)

Arizona

  • Celerion - Tempe

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2010-04
Est. Completion 2010-05
Phase Phase 1

Sponsor

VIVUS

35 total trials

What the Registry Record Tells You About NCT01117038

The ClinicalTrials.gov registry entry for NCT01117038 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (79% lower). The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Erectile Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which avanafil and enalapril is the first listed.

NCT01117038 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT01117038 about?

NCT01117038 is a clinical study titled "Drug Interaction Study of Avanafil and Enalapril or Amlodipine". The purpose of this study is to determine the change in the blood pressure and pulse rate, pharmacokinetics and the safety when avanafil is taken with either enalapril or amlodipine.

What is the current status of trial NCT01117038?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2010-04. Estimated completion is 2010-05.

What conditions does trial NCT01117038 study?

This clinical trial studies the following conditions: Erectile Dysfunction.

What interventions are being tested in trial NCT01117038?

The interventions under investigation include: avanafil and enalapril (DRUG), avanafil and amlodipine (DRUG).

Who is sponsoring clinical trial NCT01117038?

This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01117038 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Erectile Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.